Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ganeden Claims “Highest Level” Proof For Anti-Aging Probiotic

This article was originally published in The Tan Sheet

Executive Summary

Ganeden Biotech is optimistic that evidence backing the efficacy of its anti-aging probiotic Bonicel will drive success of the branded ingredient. As regulators and lawsuits target cosmetics companies over claims, science that can withstand these tests becomes more important.

You may also be interested in...



Clinique’s Scientific Language Misleads Consumers – Suit

Consumer lawsuit seeking class-action certification faults the Estee Lauder Companies for scientific language in its Clinique marketing that implies FDA approval, and for performance claims that can’t be true or they’d render the product a drug. Plaintiff’s lawyer says anti-aging marketers are “pushing the envelope.”

European Nutrition Groups Challenge EFSA Health Claims Policy

European industry trade associations file a lawsuit to block the implementation of what they call EFSA’s restrictive list of permitted health claims. The groups demand the annulment of the general function claim list and ask the EC to “correct the flaws in its approach.”

Probiotics Industry Says FDA Regulatory Bar Is Set Too High

Research on probiotics’ health benefits rapidly grows, but turning studies into label claims lags due to differences between industry, NIH and FDA about standards for claims substantiation. Attendees at a U.S. Pharmacopeia conference outline the challenges to finding common ground

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel